Cargando…
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
BACKGROUND: Cystic fibrosis (CF) is a genetic disorder causing poor mucociliary clearance in the airways and subsequent respiratory infection. The recently approved triple therapy Elexacaftor-Tezacaftor-Ivacaftor (ETI) has significantly improved the lung function and decreased airway infection of pe...
Autores principales: | Martin, Christian, Guzior, Douglas V., Gonzalez, Cely T., Okros, Maxwell, Mielke, Jenna, Padillo, Lienwil, Querido, Gabriel, Gil, Marissa, Thomas, Ryan, McClelland, Marc, Conrad, Doug, Widder, Stefanie, Quinn, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571617/ https://www.ncbi.nlm.nih.gov/pubmed/37841851 http://dx.doi.org/10.21203/rs.3.rs-3356170/v1 |
Ejemplares similares
-
A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung(✩)
por: Sosinski, Lo M., et al.
Publicado: (2022) -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety
in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022) -
ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020) -
Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)